Want to see BCPC full AI Analyst Report?
BCPC Stock Chart & Stats
$162.81
$1.96(1.20%)
At close: 4:00 PM EDT
$162.81
$1.96(1.20%)
Day’s Range― - ―
52-Week Range$139.17 - $183.90
Previous CloseN/A
Volume42.12K
Average Volume (3M)242.99K
Market Cap
$5.23B
Enterprise Value$5.58K
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$33.93M
Price to Earnings (P/E)32.7
Beta0.44
Next Earnings
Oct 23, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)5.12
Shares Outstanding32,129,837
10 Day Avg. Volume177,076
30 Day Avg. Volume242,987
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)3.98
Price to Sales (P/S)4.82
P/FCF Ratio28.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$212.00Price Target Upside30.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)5.23
Revenue Forecast (FY)$1.11B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And FCFConsistently high operating cash flow (~$220M TTM) and strong free cash flow (~$189M TTM) provide durable internal funding for R&D, marketing, buybacks and debt reduction. Robust cash conversion (OCF ~1.44x net income) supports flexibility through cycles and funds strategic investments without heavy external financing.
Conservative Balance Sheet And Low LeverageA sharp reduction in gross debt to ~$34M and very low net leverage materially lowers financial risk and increases strategic optionality. This durable balance-sheet strength supports capital allocation (repurchases, reinvestment, bolt-on M&A) and cushions the business against interest or cyclical shocks over the next several quarters.
Sustained Margin Expansion And EBITDA StreakConsistent margin expansion (adjusted EBITDA margin ~27.4%) and a 28-quarter streak of YoY adjusted-EBITDA growth reflect durable operational execution, profitable product mix and pricing power. These structural advantages support cash flow resilience and earnings quality even if volume growth moderates.
Bears Say
Modest Top-line MomentumTop-line growth has slowed to roughly ~2.7% TTM, implying the company's recent performance is more driven by margin and efficiency gains than volume expansion. This constrains longer-term earnings upside and makes results more sensitive to margin pressures or weaker end-market demand.
Elevated Input-cost ExposurePersistent commodity and input-cost inflation is a structural margin risk for a specialty-ingredients manufacturer. Even with operational offsets, sustained higher input prices can compress gross margins, force recurring price actions, and limit the durability of recent margin gains absent continued productivity improvements.
Portion Of A&H Growth Reliant On PricingWhen a meaningful share of segment growth comes from price rather than volume, earnings durability is exposed to competitive or customer pushback. If pricing tailwinds fade or input cost passthrough becomes harder, segment margins and consolidated growth could reverse, limiting sustainable organic expansion.
Balchem News
BCPC FAQ
What was Balchem’s price range in the past 12 months?
Balchem lowest stock price was $139.17 and its highest was $183.90 in the past 12 months.
What is Balchem’s market cap?
Balchem’s market cap is $5.23B.
When is Balchem’s upcoming earnings report date?
Balchem’s upcoming earnings report date is Oct 23, 2026 which is in 82 days.
How were Balchem’s earnings last quarter?
Balchem released its earnings results on Jul 31, 2026. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.275 by $0.115.
Is Balchem overvalued?
According to Wall Street analysts Balchem’s price is currently Undervalued.
Does Balchem pay dividends?
Balchem pays a Annually dividend of $0.96 which represents an annual dividend yield of 0.57%. See more information on Balchem dividends here
What is Balchem’s EPS estimate?
Balchem’s EPS estimate is 1.39.
How many shares outstanding does Balchem have?
Balchem has 32,129,837 shares outstanding.
What happened to Balchem’s price movement after its last earnings report?
Balchem reported an EPS of $1.39 in its last earnings report, beating expectations of $1.275. Following the earnings report the stock price went up 2.965%.
Which hedge fund is a major shareholder of Balchem?
Currently, no hedge funds are holding shares in BCPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Balchem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$212.00 (30.21% Upside)
$212.00 (30.21% Upside)
Blogger Sentiment
Bullish
BCPC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.79%
12-Months-Change
Fundamentals
Return on Equity
0.57%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Company Description
Balchem
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
BCPC Company Deck
BCPC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a strongly positive operational and financial performance: record revenues, profits, adjusted EBITDA, broad-based segment growth, solid cash flow, low leverage, and strategic balance sheet actions (refinancing and buybacks). Headwinds noted include elevated input costs, slightly higher operating expenses and taxes, floating-rate exposure, and some reliance on pricing in A&H. On balance the positives — consistent record results, sustained growth momentum (28 consecutive quarters of adjusted EBITDA growth), and improved financial flexibility — materially outweigh the limited headwinds.View all BCPC earnings summariesBCPC Stock 12 Month Forecast
Average Price Target
$212.00
▲(30.21% Upside)
Technical Analysis
Ownership Overview
0.67% Insiders
29.42% Mutual Funds
11.09% Other Institutional Investors
29.88% Public Companies and
Individual Investors